PLESAE PUT “CFG – 2” IN FRONT OF PROGRAM TITLE

Call For Grant 2

Stroke Prevention

TOTAL COST:  $150 non industry meeting / $250 industry meeting

Proposed launch : 2026

Intended Format : – Live, enduring, virtual/enduring 

Intended Audience: Pharmacist (primary audience), Neurologist, Primary Care Physician, Critical Care Physician, Hospitalist, Advanced Practice Providers, Nurse, Care Manager

Bayer TA Rationale for Educational Support :

Highest priority will be given to programs whose main focus is:

• Review TOAST classification of ischemic stroke, highlighting that non-cardioembolic causes of stroke represent 75% of ischemic stroke
• Review current guideline-recommended antithrombotic management strategies for secondary stroke prevention following a non-cardioembolic ischemic stroke or TIA, including contemporary studies (e.g., POINT, CHANCE, THALES) leading to these recommendations
• Raise awareness of the unmet need for treatments that can reduce the risk of recurrence of non-cardioembolic ischemic stroke without compromising safety
• Discuss dual-pathway inhibition in the context of combining an anticoagulant with an antiplatelet agent in the setting of prior stroke (e.g., COMPASS subanalysis)
• Review the coagulation cascade, focusing on differences in activation of the contact and tissue factor pathways (incl. intrinsic and extrinsic)
• Review FXI congenital deficiency data
• Discuss the significance of FXIa inhibition as a novel antithrombotic paradigm which can address current unmet needs
• Review PACIFIC-STROKE data, including key post-hoc analyses and the rationale for developing FXIa inhibitors in non-cardioembolic ischemic stroke and high-risk TIA
• Review ongoing phase III studies evaluating FXIa inhibitors for secondary stroke prevention, including OCEANIC-STROKE and LIBREXIA-STROKE

Proposal Requirements: 

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).

The proposal should include:

• Needs assessment
• Educational design and rationale for selection (where applicable)
• Learning Objectives
• Proposed Faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan
• Detailed budget

Provider Justification: 

Copy of most recent accreditation letter and status

Process 

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References

1. Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, Agafina A, Campbell B, Caso V, Mas JL, Dong Q, Turcani P, Christensen H, Ferro JM, Veltkamp R, Mikulik R, De Marchis GM, Robinson T, Lemmens R, Stepien A, Greisenegger S, Roine R, Csiba L, Khatri P, Coutinho J, Lindgren AG, Demchuk AM, Colorado P, Kirsch B, Neumann C, Heenan L, Xu L, Connolly SJ, Hart RG; PACIFIC-Stroke Investigators. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022 Sep 24;400(10357):997-1007. doi: 10.1016/S0140-6736(22)01588-4. Epub 2022 Sep 2. PMID: 36063821.
2. Greco A, Laudani C, Spagnolo M, Agnello F, Faro DC, Finocchiaro S, Legnazzi M, Mauro MS, Mazzone PM, Occhipinti G, Rochira C, Scalia L, Capodanno D. Pharmacology and Clinical Development of Factor XI Inhibitors. Circulation. 2023 Mar 14;147(11):897-913. doi: 10.1161/CIRCULATIONAHA.122.062353. Epub 2023 Mar 13. PMID: 36913497.
3. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021 Oct;20(10):795-820. doi: 10.1016/S1474-4422(21)00252-0. Epub 2021 Sep 3. PMID: 34487721; PMCID: PMC8443449.
4. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association [published correction appears in Stroke. 2021 Jul;52(7):e483-e484]. Stroke. 2021;52(7):e364-e467. doi:10.1161/STR.0000000000000375